Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

FNFranck E. Nicolini

Discussion

Loading...

Member takes

Overview

Analysis reveals longer TKI therapy duration predicts treatment-free remission in chronic myeloid leukemia patients, indicating significant outcomes.

Key Points

  • A sustained duration of deep molecular remission of over 5 years correlates significantly to treatment-free remission rates.
  • The study assessed treatment-free remission in chronic myeloid leukemia across multiple centers, with over 400 patients analyzed.
  • Univariate analyses showed that type of tyrosine kinase inhibitor used did not influence treatment-free remission rates significantly.
  • The long-term follow-up indicated a 15-year overall survival rate of 92%, underscoring the treatment’s effectiveness.

Cite This Study

Franck E. Nicolini (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e426https://doi.org/10.1182/blood-2025-5550
View Full Paper
Ask AI
Bookmark
Share